HERIZON-GEA-01 Trial

FDA Approves Zanidatamab Regimens for First‑Line HER2‑Positive Gastroesophageal Cancer

Based on Phase III survival gains, the agency added boxed warnings for severe diarrhea and embryo‑fetal harm that will shape how clinicians use the new regimens.